Amgen Inc. has showcased a robust financial performance with reported revenues of $9.56 billion, reflecting a 12.4% year-on-year increase, as it implements a partnership with the Trump administration to lower drug prices. The company anticipates continued growth driven by key drugs like Repatha and Evenity through 2026 while planning a $2.5 billion investment to enhance U.S. production and research capabilities. Despite a current EPS forecast suggesting a decline and a Zacks Rank of #3 (Hold), Amgen's impressive return on equity of 73% affirms its strong market position.
“Amgen · has a ROE of · 73% · true”
“Amgen · has a superior ROE compared to the average in the Biotechs industry · 18% · true”
“Amgen · has a debt to equity ratio of · 5.67 · true”
“Amgen · signed · agreement with the Trump administration · to lower drug prices in the United States”
“Amgen · launched · DTC program called AmgenNow · in October”
“Amgen · plans to invest · $2.5 billion · to strengthen its U.S. production and research capabilities”
“AMGEN, INC. · rates · highest · 87%”
“AMGEN, INC. · is a · large-cap growth stock · true”
“AMGEN, INC. · belongs to · Biotechnology & Drugs industry · true”
“Amgen · expects key drugs to continue to drive top-line growth · in 2026 · yes”
“Amgen · is driving top-line growth · from key medicines like Repatha and new drugs like Tavneos · in 2026”
“Amgen · expects · impact of its upcoming LOE · mitigated by new biosimilar launches”
